Study M350
Study name | Shirayama Y 2017 |
Title | Myo-inositol, glutamate, and glutamine in the prefrontal cortex, hippocampus, and amygdala in major depression |
Overall design | The aim of this study was to test the following hypotheses: 1) levels of myo-inositol would be decreased in the hippocampus and amygdala in depression, and 2) levels of glutamate would be decreased in the hippocampus and amygdala in depression. Brain metabolites were measured from the medial prefrontal cortex, hippocampus, and amygdala of drug-naive, first-episode patients with major depressive disorder (depression group, n = 22) and healthy control subjects (control group, n = 27) using 3 T proton magnetic resonance spectroscopy. Both mean absolute levels and mean ratios of metabolite to total creatine levels were compared. |
Study Type | Type1; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 >= 14 |
Sample size | 49 |
Tissue | Central; Brain; Medial prefrontal cortex; Central; Brain; Hippocampus; Central; Brain; Amygdala; |
Platform | MRS; MRS: 3 T Discovery MR750 (GE, Milwaukee, WI); |
PMID | |
DOI | |
Citation | Shirayama Y, Takahashi M, Osone F, et al. Myo-inositol, glutamate, and glutamine in the prefrontal cortex, hippocampus, and amygdala in major depression. Biol Psychiatry Cogn Neurosci Neuroimaging 2017;2(2), 196-204. |
Metabolite | myo-Inositol; L-Glutamic acid; Glutamate and Glutamine; |
